

ALL INDIA INSTITUTE OF MEDICAL SCIENCES
ANSARI NAGAR, NEW DELHI- 29
MAIN HOSPITAL STORE

Ref. No. 18/H/Tab.Asciminib-40mg/PAC/2026-27

Sub: Procurement of 'Tab. Asciminib-40mg on Proprietary basis Inviting comments thereon.

The Institute is in the process to purchase "Tab. Asciminib-40 mg" for treatment of EHS patient from M/s Novartis Healthcare Pvt. Ltd. on proprietary basis. The proposal and PAC Certifications are attached.

The above documents are being uploaded for open information to submit objections/ comments, if any, from any manufacturer regarding proprietary nature of the item within issue of 15 days from the day of issue/uploading of the notification giving reference Ref. No. 18/H/Tab.Asciminib-40mg/PAC/2026-27. The comments should be received by office of Sr. Stores Officer (H), Main Hospital Store, at AIIMS New Delhi on or before **01/10/2026 upto 12:30 P.M.** failing which it will be presumed that any other vendor is having no comment to offer and case will be decided on merit.



Sr. Stores Officer (H)

PROPRIETORY ARTICLE CERTIFICATE (PAC)

(for chemicals, spare parts, reagents, consumables etc)

- i. The indented goods are manufactured by M/s. Novartis India Limited
- ii. Item Name: Tab. Asciminib
- iii. Model/Part/Catalogue No. Item Strength: 40 mg
- iv. Reasons/ Justifications which makes the requirement proprietary
Single Manufacture

1. It is certified that market survey has been done and found that no other manufacturer is manufacturing similar/equivalent specifications which can fulfil the vital requirement of end user.
2. It is certified that the purchase is proposed to be made on proprietary usage basis because any other material/equipment/instrument chemical etc. if used will lead to deviation and affect the integrity/accuracy, validity or analysis of the assignment/patient care.

① Dr. Muneer

② Dr. Rishi

③ Dr. Sherook

डॉ. रishi धवन
Dr. RISHI DHAWAN
सहायक आचार्य/Associate Professor
रुधिर विज्ञान विभाग/Deptt. of Hematology
अ.भा.आ.सं. नई दिल्ली/A.I.I.M.S., New Delhi-29

Signature of TSEC

With name, Designation, Department and Hospital/Institute/DGHS



डॉ. शेरूख ज
Dr. Sherook. J
सहायक आचार्य/Assistant Professor
रुधिर विज्ञान विभाग/Deptt. of Hematology
अ.भा.आ.सं. नई दिल्ली/A.I.I.M.S., New Delhi-29



**Novartis Healthcare Private
Limited**

Inspire BKC
7th Floor, Bandra Kurla Complex
Bandra East, Mumbai 400051
Maharashtra, India
Tel +91 22 50243000

<https://www.novartis.com/in-en/>
CIN - U15202MH1997PTC111257

Dt. 20.08.2026

To,
Senior Store Officer,
Main Hospital Store,
AIIMS,
New Delhi- 110029

Subject - Rate Quotation Submission for Asciminib 40 mg (Kyzific 40 mg) to your esteemed institution.

Dear Ma'm/Sir,

Please find below mentioned rates of Asciminib 40 mg for your esteemed institution:-

Brand Name	Generic Name	Pack Size	Quoted Price per tab. (without GST)	GST Extra	MRP (per pack)
Kyzific 40 mg	Asciminib 40 mg	1x60	Rs.2700.28/- per tab.	0%	Rs. 202087/-

Validity Period:- Above-mentioned rates are valid against this enquiry only.

Delivery Schedule:- Goods will be delivered within 30 days from the date of receipt of your confirmed order subject to availability of stocks at our end.


Thanking you,
For Novartis Healthcare Pvt. Ltd.

Anand
Sumit

Digitally signed by Anand Sumit
DN: cn=Anand Sumit, o=Novartis,
serialNumber=2079138, c=IN
Date: 2026.08.20 18:39:41 +05'30'

Sumit Anand
Access Field Lead- Public
Key Account Management

MS. Swetha
22/8





**Novartis Healthcare Private
Limited**

Inspire BKC
7th Floor, Bandra Kurla Complex
Bandra East, Mumbai 400051
Maharashtra, India
Tel +91 22 50243000

<https://www.novartis.com/in-en/>
CIN - U15202MH1997PTC111257

Dated 20.08.2026

To,
Senior Store Officer
Main Hospital Store,
AIIMS
New Delhi- 110029

Sub:- Authorization Letter

Respected Madam/Sir,

With above reference, We wish to confirm with effective from 20.08.2026 M/s Albino Lifesciences is our authorized Stockiest for your esteemed institution to collect supply order, supply, raise invoices & collect payments thereof.

We are giving hereunder address & other details of our distributor:

M/s. Albino Lifesciences Pvt. Ltd.
M-64, Basement Lajpat Nagar-II, New Delhi-110024
Property No.221, Portion-A, Ground Floor,
Okhla Industrial Estate Phase-III, New Delhi-110020
GSTIN: 07AAACI1671E1ZX
Tel.: +011-29842893, 29842376 Fax: +011-66173539
Mobile +91 8800021934
Email: mail@albino91.com, tender.q@albino91.com

This authority letter is valid against this rate enquiry only.

Yours Sincerely
For Novartis Healthcare Private Limited

**Anand
Sumit**

Sumit Anand
Access Field Lead-Public
Key Account Management

Digitally signed by Anand Sumit
DN: dc=com, dc=Novartis,
ou=people, ou=IN,
serialNumber=2079135, cn=Anand
Sumit
Date: 2026.08.20 18:38:27 +05'30



Novartis Pharma AG
Regulatory Affairs
Global Drug Development
Lichtstrasse 35
4056 Basel
Switzerland

TO WHOMSOEVER IT MAY CONCERN

Basel, February 5, 2026

Country: India

Proprietary Authentication Certificate

Asciminib film-coated tablets 40 mg (Brand name - Kyzific®)

Dear Madam / Sir,

We, Novartis Pharma AG, a company under the laws of Switzerland, located at Lichtstrasse 35, 4056 Basel, Switzerland, do herewith confirm that **Asciminib film-coated tablets 40 mg (Brand name - Kyzific®)** is proprietary product of Novartis Pharma AG, Switzerland and the drug product is manufactured at M/s. Novartis Pharma Stein AG, Schaffhauserstrasse, 4332 Stein, Switzerland.

Asciminib film-coated tablets 40 mg (Brand name - Kyzific®)

The above product is presently being imported and solely marketed by M/s Novartis Healthcare Private Limited in India.

Yours faithfully,
Novartis Pharma AG
Basel, Switzerland

Dan Mihailescu
RA International
RA Head Pipeline Management & Regulatory Excellence

Jennifer Herman
RA International
RA Regional Coordinator

AUTHENTICATION

I, the undersigned Michael Julius Moser, notary public of the Canton of Bern (Switzerland), entered in the Bern Register of Notaries Public, with office in Bern, herewith **certify** the authenticity of the foregoing signatures of

1. Mr. Dan-Dragos MIHAILESCU, born on October 12th, 1969, Swiss citizen, resident at Rixheim, France;
2. Ms. Jennifer HERMAN, born on October 1st, 1973, German citizen, at Weil am Rhein, Germany,

whose signatures I have identified by comparison with doubtlessly authentic signatures. The signers furnished proof of identity through production of the Swiss Identity Card no. C8359908, issued February 20th, 2016 by the DFAE, Bern, and the German Identity Card n°. L9GCH9W17, issued by the City of Weil am Rhein on April 29th, 2024.

Certified at the office of the Notary public on this tenth day of February two thousand and twenty-six.

February 10th, 2026



The Notary Public:

Apostille

(Convention de La Haye du 5 octobre 1961)

1. Country: Swiss Confederation, Canton of Bern

This public document

2. has been signed by Michael Julius Moser
3. acting in the capacity of Notary
4. bears the seal / stamp of
Notary of the canton of Bern

Certified


5. at Bern
6. the 11/02/2026
7. by the State Chancellery of the canton of Bern


8. No. 2414
9. Seal / Stamp

Tax CHF 25.00

10 Signature

Caroline Rüeggsegger





**INTELLECTUAL
PROPERTY INDIA**

PATENTS | DESIGNS | TRADE MARKS
GEOGRAPHICAL INDICATIONS



सत्यमेव जयते

भारत सरकार
GOVERNMENT OF INDIA

पेटेंट कार्यालय
THE PATENT OFFICE

पेटेंट प्रमाणपत्र
PATENT CERTIFICATE
(Rule 74 of The Patents Rules)


क्रमांक : 011155858
SL No :



पेटेंट सं. / Patent No. : 419280
आवेदन सं. / Application No. : 9758/DELNP/2014
फाइल करने की तारीख / Date of Filing : 09/05/2013
पेटेंटी / Patentee : NOVARTIS AG

प्रमाणित किया जाता है कि पेटेंटी को, उपरोक्त आवेदन में यथाप्रकटित BENZAMIDE DERIVATIVES FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1 नामक आविष्कार के लिए, पेटेंट अधिनियम, 1970 के उपबंधों के अनुसार आज तारीख मई 2013 के नौवें दिन से बीस वर्ष की अवधि के लिए पेटेंट अनुदत्त किया गया है।

It is hereby certified that a patent has been granted to the patentee for an invention entitled BENZAMIDE DERIVATIVES FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1 as disclosed in the above mentioned application for the term of 20 years from the 9th day of May 2013 in accordance with the provisions of the Patents Act, 1970.



अनुदान की तारीख : 25/01/2023
Date of Grant :

पेटेंट नियंत्रक
Controller of Patent

टिप्पणी - इस पेटेंट के नवीकरण के लिए फीस, यदि इसे बनाए रखा जाना है, मई 2015 के नौवें दिन को और उसके पश्चात प्रत्येक वर्ष में उसी दिन देय होगी।

Note. - The fees for renewal of this patent, if it is to be maintained will fall / has fallen due on 9th day of May 2015 and on the same day in every year thereafter.